Narrow-band mid-wave uгltraviolet therapy in patients with mycosis fungoides

Cover Page

Cite item

Full Text

Abstract

Background. Standardization of the approach to the prescription of UVB-311 in mycosis fungoides is an urgent problem that requires prospective studies aimed at finding the most effective and safe treatment regimens.

Aim. To assess the efficacy of an optimized regimen of narrow-band medium-wave ultraviolet therapy in the treatment of patients with mycosis fungoides compared to PUVA therapy.

Methods. The authors performed a prospective non-randomized comparative study. The study enrolled 30 patients with early-stage mycosis fungoides (IA–IIA): 15 patients received UVB-311, 15 received PUVA therapy with oral administration of the photosensitizer Ammi majoris fructuum furocumarini. Therapeutic efficacy was assessed at the 10th, 20th, and final treatment sessions using the mSWAT and BSA criteria.

Results. A comparative analysis of therapeutic efficacy showed no statistically significant differences in changes in BSA and mSWAT clinical indices between UVB-311 and PUVA therapy (p > 0.05). The proportion of total response (the sum of complete and partial remission) did not differ between the treatment groups, it constituted 93.3% (n = 14).

Conclusion. In the proposed regimen, UVB-311 is comparable to PUVA in patients with early-stage mycosis fungoides.

About the authors

Anastasiia A. Vorontsova

State Research Center of Dermatovenereology and Cosmetology

Author for correspondence.
Email: nastasia08@bk.ru
ORCID iD: 0000-0002-3129-0050
SPIN-code: 8334-2890

Dermatovenerologist

Russian Federation, Moscow

Mar’yana B. Zhilova

State Research Center of Dermatovenereology and Cosmetology

Email: zhilova@cnikvi.ru
ORCID iD: 0000-0003-2545-2129
SPIN-code: 8930-4073

MD, Dr. Sci. (Med.)

Russian Federation, Moscow

Lyudmila F. Znamenskaya

State Research Center of Dermatovenereology and Cosmetology

Email: znaml@cnikvi.ru
ORCID iD: 0000-0002-2553-0484
SPIN-code: 9552-7850

MD, Dr. Sci. (Med.)

Russian Federation, Moscow

References

  1. Грибовидный микоз: клинические рекомендации / Одобрены Научно-практическим советом Минздрава России, 2023. URL: https://cr.minzdrav.gov.ru/view-cr/223_2
  2. Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome — Update 2017. Eur J Cancer. 2017;77:57–74. doi: 10.1016/j.ejca.2017.02.027
  3. Herrmann JJ, Roenigk HH Jr, Hurria A, Kuzel TM, Samuelson E, Rademaker AW, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol. 1995;33(2Pt 1):234–242. doi: 10.1016/0190-9622(95)90241-4
  4. Young A. Carcinogenicity of UVB phototherapy assessed. Lancet. 1995;345:1431–1432. doi: 10.1016/S0140-6736(95)92617-8
  5. Phan K, Ramachandran V, Fassihi H, Sebaratnam DF. Comparison of narrowband UV-B with psoralen-UV-A phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(3):335–341. doi: 10.1001/jamadermatol.2018.5204
  6. Gathers RC, Scherschun L, Malick F, Fivenson DP, Lim HW. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol. 2002;47(2):191–197. doi: 10.1067/mjd.2002.120911
  7. Dereure O, Picot E, Comte C, Bessis D, Guillot B. Treatment of early stages of mycosis fungoides with narrowband ultraviolet B. A clinical, histological and molecular evaluation of results. Dermatology. 2009;218(1):1–6. doi: 10.1159/000161114
  8. Перечень редких (орфанных) заболеваний. URL: https://minzdrav.gov.ru/documents/8048

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Efficacy of UVB-311 in the treatment of patients with infiltrative plaque sites (a) and with predominantly macular rashes (б): а — patient K. at baseline (BSA — 49.2; mSWAT — 80.4) and after treatment (BSA — 10.8; mSWAT — 10.8); б — patient L. at baseline (BSA — 17.5; mSWAT — 21.0) and after treatment (BSA — 0; mSWAT — 0)

Download (353KB)
Indexing metadata
3. Fig. 2. Changes in clinical indices during UVV-311 treatment expressed in deltas (a), percentage of reduction (б), and absolute values (в) of BSA and mSWAT (p > 0.05)

Download (338KB)
Indexing metadata
4. Fig. 3. Comparative evaluation of efficacy of PUVA and UVB-311 according to the criteria proposed by the ISCL, EORTC, and USCLC consortia

Download (249KB)
Indexing metadata
5. Fig. 4. Changes in clinical indices during PUVA therapy expressed in deltas (a), percentage of reduction (б), and absolute values (в) (p > 0.05)

Download (303KB)
Indexing metadata
6. Fig. 5. Efficacy of PUVA therapy in the treatment of patients with varying degrees of clinical manifestations: a — patient S. at baseline (BSA — 64.0; mSWAT — 99.4) and after treatment (BSA — 12.5; mSWAT — 20.5); б — patient M. at baseline (BSA — 24; mSWAT — 44) and after treatment (BSA — 17.5; mSWAT — 26.5)

Download (444KB)
Indexing metadata
7. Fig. 6. Changes in clinical BSA and mSWAT indices expressed in absolute values (a), deltas (б), and percentage of reduction (в) in UVV-311 and PUVA groups during therapy (p > 0.05)

Download (366KB)
Indexing metadata

Copyright (c) 2025 Vorontsova A.A., Zhilova M.B., Znamenskaya L.F.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).